High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation

Expert Opinion on Investigational Drugs

Volumn 19, Issue 10, 2010, Pages 1275-1295

  Glówka, Franciszek K ^a   Romaski, Michał ^a   Wachowiak, Jacek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

conditioning regimen; DNA alkylation; epoxides; hematopoietic stem cell transplantation; pediatric recipients; pharmacokinetics; regimen related toxicity; treosulfan

Indexed keywords

ALEMTUZUMAB; AMINOTRANSFERASE; AZATHIOPRINE; BETA INTERFERON; BUSULFAN; BUTHIONINE SULFOXIMINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE DERIVATIVE; CYTOSTATIC AGENT; DACARBAZINE; ETOPOSIDE; FLUDARABINE; GEMCITABINE; MELPHALAN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PACLITAXEL; TEMOZOLOMIDE; TERIFLUNOMIDE; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ALBERS SCHOENBERG DISEASE; ALKYLATION; ALOPECIA; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APLASTIC ANEMIA; AREA UNDER THE CURVE; BETA THALASSEMIA; BONE MARROW DEPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHOROID MELANOMA; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EWING SARCOMA; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTIOCYTIC SARCOMA; HISTIOCYTOSIS X; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOMA; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; MUTAGENICITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOMA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEPHROTOXICITY; OVARY CARCINOMA; PNEUMONIA; REVIEW; SHWACHMAN SYNDROME; SIDE EFFECT; SKIN PIGMENTATION; STOMATITIS; THALASSEMIA MAJOR; THROMBOCYTOPENIA; VEIN OCCLUSION; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING;

EID: 77956568136     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.517744     Document Type: Review

References (103)

1. Ljungman P, Urbano-Ispizua A, Cavazanna-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006;37:439-449
2. Pasquini MS, Wang Z. CIBMTR summary slides: current uses and outcomes of hematopoietic stem cell transplantation 2009. CIBMTR Newsl 2009;15:7-11
3. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic stem cell transplantation for patients older than 50 years of age. Blood 2005;105:1810-1814
4. Landfried K, Wolff D, Holler E. Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. Curr Opin Oncol 2009;21(Suppl 1):S29-41
5. Satwani P, Cooper N, Rao K, et al. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant 2008;41:173-182
6. Hilger RA, Harstrick A, Eberhardt W, et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998;42:99-104
7. Schuelen ME, Hilger RA, Oberhoff C, et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000;6:4209-4216
8. Gropp M, Meier W, Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 1998;71:94-98
9. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003;52:377-382
10. Treosulfan Injection (Medac UK)-Summary of Product Characteristics (SPC)-electronic Medicines Compendium (eMC). Available from: http://emc.medicines.org. uk/medicine/6431/SPC/Treosulfan+ Injection++(medac+UK) /[Last accessed 4 May 2010]
11. Treosulfan Capsules 250 mg (Medac UK)-Summary of Product Characteristics (SPC)-electronic Medicines Compendium (eMC). Available from: http://emc.medicines.org. uk/medicine/6426/SPC/Treosulfan+ Capsules+250+mg+++(Medac+UK)/[Last accessed 4 May 2010]
12. Wachowiak J, Chybicka A, Boruczkowski D, et al. Intravenous treosulfan in conditioning regimen for allogeneic HSCT from MSD in children with high risk of toxic complications related to conventional preparative. Bone Marrow Transplant 2002;30(Suppl 1) S12
13. Casper J, Knauf K, Kiefer T, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004;103:725-731
14. Beelen DW, Trenschel R, Casper J, et al. Conditioning. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005;35:233-241
15. Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulfan for myeloablative conditioning in paediatric allogeneic transplantation. Br J Haematol 2008;143:748-751
16. Sauer M, Zeidler C, Meissner B, et al. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Schwachman-Diamond syndrome. Bone Marrow Transplant 2007;39:143-147
17. Feit PW, Rastrup-Andersen N, Matagne R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3, 4-butanediol 4-methanesulfonate. J Med Chem 1970;13:1173-1175
18. Boobis A, Rawlins M, Thomas S, Wilkins M. Treosulfan. In: Dollery C, editor, Therapeutic drugs. Churchill Livingstone, Edinburgh; 1999. p. 161-162
19. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1999;79:264-266
20. Matagne R. Activity of L-threitol 1,4-bismethanesulfonate on barley chromosomes in relation to chemical transformation during treatment. Mutat Res 1967;4:621-630
21. Park S, Anderson C, Loeber R, et al. Interstrand and intrastrand DNA-DNA cross-linking by 1,2,3,4-diepoxybutane: role of stereochemistry. J Am Chem Soc 2005;127:14355-14365
22. Kligerman AD, Hu Y. Some insights into the mode of action of butadiene by examining the genotoxicity of its metabolites. Chem Biol Interact 2007;166:132-139
23. Silverman RB. DNA and DNA-interactive agents. The organic chemistry of drug design and drug action. Academic Press, San Diego; 2004. p. 226-250
24. Loeber R, Rajesh M, Fang Q, et al. Cross-linking of the human DNA repair protein O6-alkylguanine DNA alkyltransferase to DNA in presence of 1,2,3,4-diepoxybutane. Chem Res Toxicol 2006;19:645-654
25. Munkelt D, Koehl U, Kloess S, et al. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol 2008;62:821-830
26. Meinhardt G, Dayyani F, Jahrsdorfer B, et al. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 2003;122:892-899
27. Schmidmaier R, Oellerich M, Baumgart J, et al. Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Exp Hematol 2004;32:76-86
28. Werner S, Mendoza A, Hilger RA, et al. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer Chemother Pharmacol 2008;62:19-31
29. Brockmann WG, Kostotyz EL, Eick JD. Correlation of apoptotic potential of simple oxiranes with cytotoxicity. Toxicol In Vitro 2006;20:729-735
30. Yadavilli S, Martinez-Ceballos E, Snowden-Aikens J, et al. Diepoxybutane activates the mitochondrial apoptotic pathway and mediates apoptosis in human lymphoblasts through oxidative stress. Toxicol In Vitro 2007;21:1429-1441
31. Yadavilli S, Muganda PM. Diepoxybutane induces p53-mediated apoptosis in human lymphoblasts. Toxicol Appl Pharmacol 2004;195:154-165
32. Schlade-Bartusiak K, Rozik K, Laczmanska I, et al. Influence of GSTT1, mEH, CYP2E1 and RAD51 polymorphism on diepoxybutane-induced SCE frequency in cultured human lymphocytes. Mutat Res 2004;558:121-130
33. Kim MY, Tretyakova N, Wogan GN. Mutagenesis of the supFGene by stereoisomers of 1,2,3,4-diepoxybutane. Chem Res Toxicol 2007;20:790-797
34. Lee DH, Kim TH, Lee SY, et al. Mutations induced by 1,3-butadiene metabolites, butadiene diolepoxide, and 1,2,3,4-diepoxybutane at the Hprt locus in CHO-K1 cells. Mol Cells 2002;14:411-419
35. Neale MH, Myatt NE, Khoury GG, et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 2001;11:601-609
36. Neale MH, Myatt N, Cree IA, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999;79:1487-1493
37. Kopf-Maier P, Sass G. Antitumor activity of treosulfan against human breast carcinomas. Cancer Chemother Pharmacol 1992;31:103-110
38. Kopf-Maier P, Sass G. Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol 1996;37:211-221
39. Kopf-Maier P. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro. In vivo 1998;12:275-288
40. Feyerabend S, Feil G, Krug J, et al. Cytotoxic effects of treosulfan on prostate cancer cell lines. Anticancer Res 2007;27:2403-2408
41. Lanvers-Kaminsky C, Bremer A, Dirksen U, et al. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anticancer Drugs 2006;17:657-662
42. Fichtner I, Becker M, Baumgart J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 2003;39:801-807
43. Neuber K, Dieck A, Blodorn-Schlicht N, et al. Treosulfan is an effective alkylating cystostatic for malignant melanoma in vitro and in vivo. Melanoma Res 1999;9:125-132
44. O'Neill PA, Butt M, Eswar CV, et al. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. Melanoma Res 2006;16:245-248
45. Keilholz U, Schuster R, Schmittel A, et al. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumors. Eur J Cancer 2004;40:2047-2052
46. Corrie PG, Shaw J, Spanswick VJ, et al. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br J Cancer 2005;92:1997-2003
47. Neuber K. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials. Recent Results Cancer Res 2003;161:159-179
48. Breitbach GP, Meden H, Schmid H, et al. Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study. Anticancer Res 2002;22:2923-2932
49. Vermorken JB. Second-line randomized trials in epithelial ovarian cancer. International J Gynecolo Cancer 2008;18(Suppl 1):59-66
50. Neuber K, Reinhold U, Deutschmann A, et al. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. Melanoma Res 2003;13:81-85
51. Westerhof GR, Ploemacher RE, Boudewijn A, et al. Comparison of different busulfan analogues of hematopoietic stem cell and promotion of donor type chimerism in murine bone marrow transplant recipients. Cancer Res 2000;60:5470-5478
52. van Pel M, van Bruegel DWJG, Vos W, et al. Towards a myeloablative regimen with clinical potential I: treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant 2003;32:15-22
53. Ploemacher RE, Johnson KW, Rombouts EJC, et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004;10:236-245
54. Sjoo F, Hassan Z, Abedi-Valugerdi M, et al. Myeloablative and immunosupressive properties of treosulfan in mice. Exp Hematol 2006;34:115-121
55. Giebel S, Wojnar J, Krawczyk-Kulis M, et al. Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia. Ann Transplant 2006;11:23-27
56. Wachowiak J, Chybicka A, Kowalczyk J, et al. Treosulfan-based preparative regimen for allogeneic hematopoietic stem cell transplantation in children with increased risk of conventional regimen toxicity. Blood 2005;106:500a-1a
57. Wachowiak J, Grund G, Sykora KW, et al. Treosulfan-based conditioning regimen for allogeneic transplantation in children congenital non-malignant disorders-retrospective study. Bone Marrow Transplant 2008;41(Suppl 1):S295
58. Kopadze T, Dehmel T, Mylius HA, et al. Treosulfan impedes the migration of immunocompetent cells. J Neurol 2007;254:1457-1458
59. Weissert R, Wiendl H, Pfrommer H, et al. Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J Neuroimmunol 2003;144:28-37
60. Wiendl H, Kieseier BC, Weissert R, et al. Treatment of active secondary progressive multiple sclerosis with treosulfan. J Neurol 2007;254:884-889
61. Atzpodien J, Terfloth K, Fluck M, Reitz M. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol 2008;62:685-688
62. Cree IA, Neale MH, Reinhold U, Kurbacher CM. Treosulfan and gemcitabine. J Cancer Res Clin Oncol 2005;131:329-330
63. Breidenbach M, Rein D, Schondorf T, et al. Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. Anticancer Drugs 2003;14:341-346
64. Wick W, Stock J, Seyfried J, et al. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. Int J Oncol 2002;21:213-220
65. Baumann P, Mandl-Weber S, Volkl A, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009;8:366-375
66. Turci R, Sottani C, Ronchi A, Minoia C. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett 2002;134:57-64
67. Harstrick A, Wilke H, Klaassen U, et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996;19:153-156
68. Hilger RA, Gabriele J, Oberhoff C, et al. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol 2000;45:483-488
69. Koenigsmann M, Mohren M, Jentsch-Ullrich K, et al. Conditioning regimens. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 2004;34:477-483
70. Bojko P, Scheulen ME, Hilger R, et al. High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. J Cancer Res Clin Oncol 2001;127:243-250
71. Wagner H, Baumgart J, Andreesen R, et al. Dose-escalation of treosulfan in a high-dose-protocol: a classical alkylating agent new in high-dose combination chemotherapy. Proc Am Soc Clin Oncol 2000;19:abstract 208
72. Baynes R, Parchment R, Dansey R, et al. Phase I evaluation of high dose melphalan, DTIC and treosulfan (MDT) in previously treated metastatic breast and ovarian cancer. Proc Am Soc Clin Oncol 2000;19:abstract 585
73. Bock J, Doenitz A, Andreesen R, et al. Pericarditis after high-dose chemotherapy: more frequent than expected? Onkologie 2006;29:321-324
74. Bojko P, Hilger RA, Ruehm SG, et al. Post-transplant complications. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;31:487-491
75. Shimoni A, Hardan I, Shem-Tov N, et al. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma 2007;48:2352-2359
76. Kroger N, Shimoni A, Zabelina T, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006;37:339-344
77. Holowiecki J, Giebel S, Wojnar J, et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukemia. Br J Haematol 2008;142:284-292
78. Schmidt-Hieber M, Blau IW, Tenschel R, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2007;39:389-396
79. Baronciani D, Rambaldi A, Iori AP, et al. Treosulfan/fludarabine as an allogeneic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol 2008;83:717-720
80. Bernardo ME, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol 2008;143:548-551
81. Greystoke B, Bonanomi S, Carr TF, et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 2008;142:257-262
82. Meissner B, Borkhardt A, Dilloo D, et al. Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukemia. Bone Marrow Transplant 2007;40:945-949
83. Welsh J, Stuart JFB, Soukop M, et al. The pharmacokinetics of oral and iv treosulfan. Br J Cancer 1982;46:467
84. Hilger RA, Baumgart J, Scheulen ME, et al. Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther 2004;42:654-655
85. Muller H, Hilger R. Curative and palliative aspects of regional chemotherapy in combination with surgery. Support Care Cancer 2003;11:1-11
86. Glowka FK, Karazniewicz-Lada M, Grund G, Wachowiak J. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetics studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. J Chromatogr B 2007;850:569-574
87. Glowka FK, Karazniewicz-Lada M, Grund G, et al. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic hematopoietic SCT. Bone Marrow Transplant 2008;42:S67-70
88. Drabko K, Zawitkowska-Klaczynska J, Wojcik B, et al. Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma. Pediatr Transplant 2005;9:618-621
89. Blau IW, Schmidt-Hieber N, Leschinger N, et al. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Ann Hematol 2007;86:583-589
90. Markiewicz M, Wojciechowska M, Wylezol I, et al. First two successful unrelated bone marrow transplantations for paroxysmal nocturnal hemoglobinuria in Poland. Ann Transplant 2005;10:26-30
91. Fruehauf S, Buss EC, Topaly J, et al. Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood stem cell transplantation with high doses of CD34+ cells results in hematologic responses-follow-up of three patients. Haematologica 2005;90:17-20
92. Klaudel-Dreszler MA, Kalwak K, Kurenko-Deptuch M, et al. Treoulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC. Int J Hematol 2009;90:571-575
93. Shimoni A, Rand A, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation using fludarabine/treosulfan conditioning regimen compared with busulfan-based myeloablative and reduced-intensity conditioning in patients with AML and MDS; relative outcomes depend on disease status at transplantation [abstract 3358]. 51st ASH Annual Meeting and Exposition; 5-8 December 2009 EMEA/COMP/371/04; London, 22 November 2004 Available from: http://www.ema.euro- pa.eu/pdfs/human/comp/opinion/037104en.pdf [Last accessed 5 May 2010]
94. Wachowiak J, Chybicka A, Kowalczyk JR, et al. Treosulfan-based preparative regimen for second hematopoietic stem cell transplantation in children with advanced hematologic malignancies. Bone Marrow Transplant 2005;35(Suppl 1):S96-7
95. Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol 2007;2:75-91
96. Hoy SM, Lyseng-Williamson KA. Intravenous busulfan in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Pediatr Drugs 2007;9:271-278
97. European Medicines Agency-Human Medicines-Busilvex. Busilvex-EPAR: Product Information. Available from: http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/000472/human-med-000681. jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d124 [Last accessed 2 August 2010] IV BUSULFEX (busulfan) Injection.
98. Full prescribing information. Available from: http://www.ivbusul-fex. com/0608L-0078A-Otsuka- IVBUSULFEX-Injection-PI.pdf [Last accessed 2 August 2010].
99. Bartelink IH, Bredius RGM, Ververs TT, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008;14:88-98
100. Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:307-314
101. Nishikawa T, Okamoto Y, Tanabe T, et al. Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation. Bone marrow Transplant 2010;45:602-604
102. Buchali A, Feyer P, Groll J, et al. Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation. Radiother Oncol 2000;54:157-162
103. Bond JA, Medinsky MA. Insights into the toxicokinetics and toxicodynamics of 1,3-butadiene. Chem Biol Interact 2001;135-136:599-614